Drug Profile
LY 2525623
Alternative Names: Anti-IL-23 antibody - Eli Lilly; Anti-IL-23 MAb - Eli Lilly; LY2525623Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
- Mechanism of Action Inflammation mediator inhibitors; Interleukin 23 inhibitors; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Plaque psoriasis
Most Recent Events
- 11 Nov 2010 Pharmacodynamics data from a preclinical study in Autoimmune arthritis presented at the 74th Annual Scientific Meeting of the American College of Rheumatology and the 45th Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2010)
- 01 Mar 2010 Suspended - Phase-II for Plaque psoriasis in Canada (IV)
- 01 Mar 2010 Suspended - Phase-II for Plaque psoriasis in USA (IV)